Rationale: Catecholaminergic polymorphic ventricular tachycardia is an inherited disease that predisposes to cardiac arrest and sudden death. The disease is associated with mutations in the genes encoding for the cardiac ryanodine receptor (RyR2) and cardiac calsequestrin (CASQ2). CASQ2 mutations lead to a major loss of CASQ2 monomers, possibly because of enhanced degradation of the mutant protein. The decrease of CASQ2 is associated with a reduction in the levels of Triadin (TrD) and Junctin (JnC), two proteins that form, with CASQ2 and RyR2, a macromolecular complex devoted to control of calcium release from the sarcoplasmic reticulum.
C atecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease that predisposes to cardiac arrest and to sudden death. 1, 2 In 2001, we showed that dominant CPVT is caused by mutations in the gene encoding for the cardiac ryanodine receptor (RyR2). 3 Soon after, Lahat et al 4 identified mutations in the gene encoding for the cardiac calsequestrin (CASQ2) in families affected by recessive CPVT.
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CASQ2 acts as a calcium buffer inside the sarcoplasmic reticulum and plays a critical role in the physiology of calcium release. Data from knock-in mice 5, 6 showed that even a single amino acid replacement leads to a major loss of CASQ2 monomers, possibly because of enhanced degradation of the mutant protein. 6 CASQ2 decrease leads to a reduction in the levels of triadin (TrD) and junctin (JnC), two proteins that form, with CASQ2 and RyR2, a macromolecular complex devoted to control calcium release from SR.
Here, we test the hypothesis that delivery of exogenous CASQ2 by viral gene transfer to CASQ2 knockout (CASQ2 KO ) mice is able to restore levels of CASQ2, TrD, and JnC, to revert electrophysiological and morphological abnormalities caused by CASQ2 ablation, and to prevent life-threatening arrhythmias. If confirmed, then our hypothesis will prove the concept that viral gene transfer may have clinical application in recessive CPVT.
Methods
An expanded Methods section is provided in the Online Supplement.
Viral Construct
We generated an adeno-associated serotype-9 vector containing the cDNA of the murine CASQ2 gene (Online Figure IA) . The cDNA was cloned into a bicistronic (pIRES) eukaryotic expression vector and subcloned into the multiple cloning site of pAAV2.1-CMV-eGFP containing the cytomegalovirus promoter and the green fluorescent protein (eGFP) as reporter gene.
Reverse-Transcription Polymerase Chain Reaction
Total RNA was extracted and purified from myocytes, liver, lung, skeletal muscle, testis, and ovary of wild-type (WT) mice and of CASQ2 KO mice infected with the AAV9-CASQ2 construct tagged with eGFP (CASQ2 INF-KO ). Reverse-transcription polymerase chain reaction was performed using tissue-specific RNA (iScript cDNA Synthesis kit; Bio-Rad Laboratories) and samples were analyzed on agarose gel.
Immunoblotting was performed as previously described 6 using the following antibodies: anti-CASQ2 (PA1-913; ABR), anti-Triadin (sc-33393; Santa Cruz), anti-junctin (kindly provided by Dr B.C. Knollmann), and anti-actin (sc-1616-R; Santa Cruz) as reference protein. Confocal microscopy was used for indirect immunofluorescent labeling of cardiac myocytes from WT, CASQ2 KO , and CASQ2 INF-KO mice was performed with primary antibodies anti-RyR2, anti-CASQ2, anti-Junctin, or anti-Triadin, as previously described. 6 Secondary antibodies were Alexa Fluor 405 goat antimouse and Alexa Fluor 546 goat anti-rabbit IgG. Images were obtained in a Leica TCS-SP5 II microscope.
Electron Microscopy
Fixed hearts were embedded in an epoxy resin and ultrathin sections were cut, stained, and analyzed as previously described. 6
In Vivo and In Vitro Electrophysiology
Ventricular myocytes were enzymatically dissociated using aortic retrograde perfusion. Action potentials were recorded with patchclamp pipettes in current-clamp configuration and analyzed with pCLAMP 9.2 (Axon Instruments). ECG was recorded using subcutaneous telemetric recorders (DSI).
Statistics
Statistical analysis was performed using SPSS version 18. Data are reported as meanϮSEM. Continuous variables were analyzed by unpaired t test or analysis of variance using Bonferroni as a post hoc test, as appropriate. Categorical variables were analyzed by contingency tables with Fisher exact test. PϽ0.05 was considered statistically significant.
Results
Mice were infected at birth by intraperitoneal injection of AAV9-CASQ2 and studied at 20 weeks of age. Cardiac myocytes isolated from CASQ2 INF-KO mice showed that 50% to 60% of cells expressed the transgene as indicated by eGFP fluorescence ( Figure 1C ). Infection was not associated with histological abnormalities of the heart (Online Figure IB) . Evaluation of different organs showed the absence of eGFP in lung, ovary, and testis, whereas a weak positive signal was detected in liver and skeletal muscle (Online Figures IIA, IIB). Expression analysis of CASQ2, TrD and JnC was performed by real-time polymerase chain reaction ( Figure  1D ) and Western blot ( Figure 1A , 1B) in CASQ2 WT (WT), CASQ2 KO (KO), and CASQ2 INF-KO mice; on infection, expressions of the three proteins were restored to levels comparable to those of WT mice.
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Immunofluorescence studies showed that exogenous CASQ2, TrD, and JnC were properly localized in myocytes derived from CASQ2 INF-KO mice ( Figure 2C , Online Figure  III) ; confocal microscopy showed that virally induced CASQ2 colocalized with endogenous RyR2 as occurs in WT mice ( Figure 2 ). By electron microscopy, we investigated whether ultrastructural abnormalities of calcium release units in CASQ2 KO mice were also reverted by CASQ2 gene transfer (Figure 3 , Online Figure IV ). Calcium-release units are formed by the close apposition of T tubules to junctional sarcoplasmic reticulum (jSR). In electron microscopy images, CASQ2 appears as electrodense chain-like polymers that hold together the opposite sides of the jSR membranes, conferring them the typical narrow and flat profile seen in CASQ2 WT mice ( Figure 3A, 3D ). It has been reported that absence of CASQ2 in CASQ2 KO myocytes induces disappearance of the chain-like polymers and widening of the jSR lumen. 7 Our experiments confirm those findings; the width of jSR lumen increased ( Figure 3D , 3E) from 26Ϯ0.3 nm to 37Ϯ1.2 nm in CASQ2 WT and CASQ2 KO myocytes (PϽ0.001), respectively, and returned to normal size in CASQ2 INF-KO myocytes (21Ϯ0.3 nm; analysis of variance PϽ0.001; Figure 3C , 3F). This observation is important because it shows that toxicity induced by CASQ2 overexpression in CASQ2 WT mice and the peculiar jSR swelling do not develop when CASQ2 overexpression is performed on the null background.
Action potential recording was performed in CASQ2 KO and in CASQ2 INF-KO myocytes to test susceptibility to development of delayed after-depolarizations and triggered activity during ␤-adrenergic stimulation. A remarkable reduction of isoproterenol (30 nmol/L) induced triggered action potentials was observed in CASQ2 INF-KO ( Figure 4A ) as compared with CASQ2 KO (from 70% in KO to 5% in CASQ2 INF-KO myocytes; PϽ0.001) or CASQ2 empty-vector and GFP-negative CASQ2 INF-KO myocytes (Online Figures V, VI) .
Arrhythmias susceptibility was investigated in vivo in mice instrumented with ECG telemetry. A striking reduction of ventricular tachycardia during epinephrine (2 mg/kg) stimulation was observed. Ventricular tachycardia occurrence decreased from 15/15 in CASQ2 KO mice to 1/10 among CASQ2 INF-KO mice (PϽ0.001; Figure 4B ). Interestingly, CASQ2 INF-KO mice also showed normalization of heart rate that increased to values similar to those of WT mice (WT: 
Discussion
CPVT is associated with mutations in the CASQ2 gene and is a highly lethal recessive disease characterized by absence or drastic reduction of cardiac calsequestrin, a protein critical for the regulation of cytoplasmic calcium homeostasis in cardiac myocytes. Treatment of patients is based on the use of antiadrenergic intervention such as ␤-blockers and left sympathetic denervation. 2 Recently, it was proposed that flecainide, a sodium channel blocker, may reduce the propensity for development of delayed after-depolarizations and triggered activity in CPVT. 9, 10 In dealing with a life-threatening disease like CPVT, the search for a therapeutic approach that attempts to revert molecular, structural, and functional abnormalities of the disease is reasonable. In the present study, we exploited our KO model of recessive CPVT caused by lack of CASQ2 to explore whether viral gene transfer using AAV9 engineered to carry the CASQ2 gene and whether it is able to revert the complex set of abnormalities observed in CASQ2 KO mice mimicking the clinical manifestations of CPVT. The study of the CASQ2 KO mouse, as well of different knock-in mice carrying CASQ2 mutations, [5] [6] [7] highlighted that either absence (KO mice) or reduction (knock-in mice) of CASQ2 levels in the heart induces a similar spectrum of abnormalities. As a consequence, the distinguishing features of recessive CPVT include: (1) severe reduction of the jSR proteins TrD and JnC that, together with CASQ2, regulate RyR2-mediated release of calcium from the SR; (2) ultrastructural changes of the jSR; (3) development of adrenergically mediated diastolic delayed after-depolarizations and triggered activity; and (4) development of sustained polymorphic or bidirectional ven- Electron micrographs from thin sections of age-matched CASQ2 wild-type (WT; A and D), CASQ2 knockout (KO, B and E) , and infected CASQ2 knockout (INF, C and F) hearts: transverse tubules (TT) are shaded in yellow. In CASQ2 WT (A and D) myocytes, the jSR present a narrow and flat profile (green), with CASQ2 visible as chain-like electron-dense polymers (black arrow), whereas in CASQ2 KO (B and E) myocytes the jSR is wider and empty. tricular tachycardia elicited by stress or emotion. This complex phenotype results from the absence of CASQ2 during embryonic development; therefore, it challenges the view that restoration of the missing protein in adults may revert phenotypic abnormalities. The mere quantitative restoration of CASQ2, in fact, does not imply that the protein will properly localize and will re-establish physiological interactions with TrD and JnC in the appropriate stochiometry. 8 Likewise, it is difficult to predict whether overexpressed CASQ2 will revert the ultrastructural abnormalities of the calcium-release units, leading to an antiarrhythmic effect. With these challenges in mind, we designed an experimental protocol that verifies the rescue of all the key defects that characterize the KO model of CPVT. Results showed that 50% of myocytes express the transgene, suggesting that the heart of such infected mice resembles that of heterozygous KO mice that are asymptomatic and do not present cardiac arrhythmias, 6 just like the heterozygous parents of affected homozygous individuals. Interestingly, in our experiments, the CASQ2 increase was accompanied by restoration of the levels of TrD and JnC and by normalization of ultrastructural abnormalities. One of our concerns in the design of the study was the possibility that viral gene transfer would induce overexpression of CASQ2, leading to the loss of the physiological ratio between CASQ2 and JnC/TrD, leading to the "toxic" effects observed in transgenic mice overexpressing CASQ2 8 and characterized by jSR swelling. Quite on the contrary, long-term gene delivery in KO mice was able to normalize ultrastructural defects of calcium-release units in the majority of myocytes. By electron microscopy, only approximately 2% of myocytes displayed overswelling of the jSR; this observation (Online Table I and Online Figure VII ) supports the view that there is heterogeneity in the amount of protein that is produced in response to infection in each cell. Although 50% of cells appear to be infected as judged by eGFP labeling (green color), the actual production of the transfected CASQ2 protein is probably more than an average 50% increase, as inferred by the Western blot data ( Figure  1A, 1B) . Interestingly, despite heterogeneity of the infection rate and its efficiency, the relevant consequence of viral gene transfer is normalization of jSR morphology in most infected cells (Online Table I ) and suppression of electrophysiological abnormalities and arrhythmias in vivo. Online Figure VII shows that re-expression of CASQ2 by viral infection may cause morphological changes in the jSR correlated with different levels of CASQ2 spanning from absence of CASQ2 (Online Table I ) to presence of diffuse CASQ2 (Online Figure VIIC) to restoration of the physiological polymer-like structure (Figure 3 ) to CASQ2 overexpression causing overswelling of the SR (Online Figure VIIB) . After observing the normalization of the molecular and ultrastructural abnormalities of CASQ2 KO mice, we anticipated that the substrate for development of triggered activity probably had been eliminated. Accordingly, in vitro and in vivo studies documented that electrophysiological abnormalities and arrhythmogenesis in vivo were completely suppressed in the KO mice infected with the AAV9-CASQ2, supporting the view that arrhythmogenesis is the consequence of the complex set of abnormalities that occurs in response to CASQ2 decrease or absence.
Our data prove that systemic administration of cardiacspecific viral vectors to deliver CASQ2 to the heart of CASQ2 KO mice is able to revert all the abnormalities reported in this CPVT mouse model. Considering that recently the CUPID trial 11 demonstrated the safety of AAV-mediated gene transfer in humans, we suggest that development of CASQ2 viral gene transfer could have clinical application for severely affected recessive CPVT resistant to conventional therapy. As part of our commitment to bring gene therapy to the clinical arena, we now need to investigate the durability of the AAV approach and whether the viral gene transfer will work in adult mice as well as in newborns.
